Amneal Pharmaceuticals is trading 4.34% up at $18.02, with no clear company-specific catalyst identified for August 14, 2026.
- Recent support may reflect lingering investor interest after strong second-quarter results, raised 2026 guidance, and the completed Kashiv BioSciences acquisition, though those developments predate the current move.
- The broader market is modestly weaker, making today’s gain appear stock-specific or flow-driven rather than market-wide.